Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,452
  • Shares Outstanding, K 17,559
  • Annual Sales, $ 460 K
  • Annual Income, $ -5,800 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 0.79
  • Price/Sales 33.09
  • Price/Cash Flow N/A
  • Price/Book 2.27
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.59
  • Most Recent Earnings $-0.15 on 04/14/25
  • Next Earnings Date 07/11/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 05/31/25
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.15
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8200 +8.04%
on 06/26/25
1.1000 -19.46%
on 06/11/25
-0.1141 (-11.41%)
since 06/09/25
3-Month
0.8200 +8.04%
on 06/26/25
1.6900 -47.58%
on 04/24/25
-0.5141 (-36.72%)
since 04/09/25
52-Week
0.8200 +8.04%
on 06/26/25
4.3800 -79.77%
on 08/30/24
-1.6941 (-65.66%)
since 07/09/24

Most Recent Stories

More News
Fed Meeting, U.S. Jobs in Focus for This Week

Tuesday U.S. Economic Lookahead NFIB optimism index (June) Consumer credit (May) ...

AZZ : 100.93 (+2.15%)
SAR : 24.32 (-2.88%)
CAG : 20.38 (-1.31%)
MTY.TO : 45.35 (+3.75%)
UNTY : 52.33 (+0.04%)
LEXX : 0.8859 (+0.67%)
PENG : 23.43 (+10.57%)
DAL : 50.70 (+0.36%)
BSET : 16.99 (+4.75%)
LEVI : 19.40 (-0.61%)
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing...

LEXXW : 0.1497 (-0.20%)
LEXX : 0.8859 (+0.67%)
Lexaria Announces $2 Million Registered Direct Offering of Common Stock

KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it...

LEXXW : 0.1497 (-0.20%)
LEXX : 0.8859 (+0.67%)
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry

LEXXW : 0.1497 (-0.20%)
LEXX : 0.8859 (+0.67%)
Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss

LEXXW : 0.1497 (-0.20%)
LEXX : 0.8859 (+0.67%)
Lexaria's Human GLP-1 Study #5 Begins Dosing

Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide

LEXXW : 0.1497 (-0.20%)
LEXX : 0.8859 (+0.67%)
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®

LEXXW : 0.1497 (-0.20%)
LEXX : 0.8859 (+0.67%)
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Lexaria executing a triple-pronged strategy in obesity and diabetes

LEXXW : 0.1497 (-0.20%)
LEXX : 0.8859 (+0.67%)
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

5th study arm in 12-week Phase 1b Study receives lead clinical site approval

LEXXW : 0.1497 (-0.20%)
LEXX : 0.8859 (+0.67%)
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Pursuing the world's first-ever orally-dosed liraglutide

LEXXW : 0.1497 (-0.20%)
LEXX : 0.8859 (+0.67%)

Business Summary

Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules....

See More

Key Turning Points

3rd Resistance Point 0.9173
2nd Resistance Point 0.9086
1st Resistance Point 0.8973
Last Price 0.8859
1st Support Level 0.8773
2nd Support Level 0.8686
3rd Support Level 0.8573

See More

52-Week High 4.3800
Fibonacci 61.8% 3.0201
Fibonacci 50% 2.6000
Fibonacci 38.2% 2.1799
Last Price 0.8859
52-Week Low 0.8200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar